COVID19 vaccine, a senior government official said."After a thorough evaluation, the DCGI has given approval to SII to perform phase-II, III clinical trial based on the recommendations of the Subject Expert Committee (SEC)," the official source told ANI."As a rapid regulatory response, the proposal was deliberated in the SEC through a virtual meeting earlier this week.
And after considering the data generated on the vaccine in phase-1, 2 of the Oxford University trial, the committee recommended granting permission to conduct phase 2, 3 clinical trials of COVISHIELD (SII-ChAdOx1 nCoV-19) healthy adult subjects at risk in the country," the official said.As per the study design, each subject will be administered two doses 4 weeks apart (First.